CAS 184036-34-8|sitaxsentan

Introduction：Basic information about CAS 184036-34-8|sitaxsentan, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. sitaxsentan BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	sitaxsentan
CAS Number	184036-34-8	Molecular Weight	454.90500
Density	1.6g/cm3	Boiling Point	600.4ºC at 760 mmHg
Molecular Formula	C₁₈H₁₅ClN₂O₆S₂	Melting Point	/
MSDS	/	Flash Point	316.9ºC

Names

Name	N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide
Synonym	More Synonyms

sitaxsentan BiologicalActivity

Description	Sitaxsentan (IPI 1040; TBC 11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure.IC50 value:Target: ETA receptor
Related Catalog	Signaling Pathways >>GPCR/G Protein >>Endothelin ReceptorResearch Areas >>Cardiovascular Disease
References	[1]. Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19(1):e1-2. [2]. Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. Epub 2011 Nov 2. [3]. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2. [4]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6. [5]. Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011 Apr;123(7-8):248-52. Epub 2011 Mar 31.

Description

Sitaxsentan (IPI 1040; TBC 11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure.IC50 value:Target: ETA receptor

Related Catalog

Signaling Pathways >>GPCR/G Protein >>Endothelin ReceptorResearch Areas >>Cardiovascular Disease

References

[1]. Chin M, Levy RD, Yoshida EM, Byrne MF.Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.Can Respir J. 2012 Jan-Feb;19(1):e1-2.

[2]. Sandoval J, et al. STRIDE-4 investigators.Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.Pulm Pharmacol Ther. 2012 Feb;25(1):33-9. Epub 2011 Nov 2.

[3]. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.Vasc Health Risk Manag. 2011;7:119-24. Epub 2011 Mar 2.

[4]. Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6.

[5]. Kaehler, et al. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wien Klin Wochenschr. 2011 Apr;123(7-8):248-52. Epub 2011 Mar 31.

Chemical & Physical Properties

Density	1.6g/cm3
Boiling Point	600.4ºC at 760 mmHg
Molecular Formula	C₁₈H₁₅ClN₂O₆S₂
Molecular Weight	454.90500
Flash Point	316.9ºC
Exact Mass	454.00600
PSA	144.35000
LogP	5.11500
Vapour Pressure	2.25E-14mmHg at 25°C
Index of Refraction	1.687
InChIKey	PHWXUGHIIBDVKD-UHFFFAOYSA-N
SMILES	Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2
Storage condition	2-8℃

Synonyms

Sitaxsentan

Sitax

Recommended......